Andrea Lobo,  —

Andrea Lobo is a Science writer at BioNews. She holds a Biology degree and a PhD in Cell Biology/Neurosciences from the University of Coimbra-Portugal, where she studied stroke biology. She was a postdoctoral and senior researcher at the Institute for Research and Innovation in Health in Porto, in drug addiction, studying neuronal plasticity induced by amphetamines. As a research scientist for 19 years, Andrea participated in academic projects in multiple research fields, from stroke, gene regulation, cancer, and rare diseases. She authored multiple research papers in peer-reviewed journals. She shifted towards a career in science writing and communication in 2022.

Articles by Andrea Lobo

Elder woman found to have acquired angiodema after tongue swelling

A 61-year-old woman in the U.S. was diagnosed with acquired angioedema and an underlying lymphoproliferative disorder after she sought treatment in an emergency department for sudden tongue swelling and difficulties in talking and swallowing, according to a case study. Lymphoproliferative disorders are characterized by the uncontrolled production of lymphocytes,…

Survey of US doctors estimates prevalence of HAE-nl-C1INH

The number of cases of hereditary angioedema with normal C1 inhibitor (HAE-nl-C1INH) within the U.S. was estimated to be between 1,230 and 1,331 from May 2019 and April 2020, according to a survey conducted among U.S. physicians. Patients waited a mean of six years to receive a diagnosis, which…

Woman with HAE, normal C1-INH has attacks despite preventive care

Despite long-term preventive treatment, a 38-year-old woman with hereditary angioedema (HAE) with normal C1-inhibitor levels had severe episodes of disease worsening, as described in a recent case report. The life-threatening sequelae and decreased quality of life illustrate the need for more research with this rare form of HAE, according…

Pregnancy Not Linked to Worse Disease in Women With HAE: Study

Women with hereditary angioedema (HAE) who have been pregnant multiple times did not experience outcomes of significant disease worsening during pregnancy, a study in Turkey found. A majority did report a greater frequency of HAE attacks during pregnancy, but this was not statistically significant, according to researchers. In patients…

Takhyrzo Found to Be Effective HAE Treatment Across Minority Groups

The efficacy and safety of Takhzyro (lanadelumab) in preventing hereditary angioedema attacks are similar across different racial and ethnic groups, according to an analysis of data from a Phase 3 trial and its open-label extension study. However, with few patients from minorities participating in clinical trials, conclusions are…